What is Gelesis Holdings Earnings Power Value (EPV)?
As of Jun23, Gelesis Holdings's earnings power value is $-0.74. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Gelesis Holdings Earnings Power Value (EPV) Historical Data
The historical data trend for Gelesis Holdings's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gelesis Holdings Earnings Power Value (EPV) Chart
|
Gelesis Holdings Annual Data
|
|
Trend |
Dec21 |
Dec22 |
| Earnings Power Value (EPV) |
|
- |
- |
|
Gelesis Holdings Quarterly Data
|
|
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Gelesis Holdings's Earnings Power Value (EPV)
For the Biotechnology subindustry, Gelesis Holdings's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelesis Holdings's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Gelesis Holdings's Earnings Power Value (EPV) falls into.
Gelesis Holdings Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Gelesis Holdings (Gelesis Holdings) Business Description
Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
| Raju S Kucherlapati |
director |
77 LOUIS PASTEUR AVENUE, BOSTON MA 02115 |
| Bomsmaster Llc |
10 percent owner |
195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510 |
| Paul R. Fonteyne |
director |
C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116 |
| Hpso Spv Ltd |
10 percent owner |
SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA |
| Alessandro Sannino |
officer: Lead Project Scientist |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Dominic Perks |
director |
GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116 |
| David A. Pass |
officer: Chief Op. & Comm. Officer |
GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116 |
| Elaine Chiquette |
officer: Chief Scientific Officer |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Jane Wildman |
director |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Harry L. Leider |
officer: Chief Medical Officer |
C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
| Clayton Christopher |
director |
2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704 |
| Health Plc Puretech |
10 percent owner |
6 TIDE STREET, SUITE 400, BOSTON MA 02210 |
| Ssd2, Llc |
10 percent owner |
142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511 |
| Yishai Zohar |
director, officer: President & CEO |
C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116 |
| Elon Boms |
10 percent owner |
C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510 |
Gelesis Holdings (Gelesis Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSHQ has been successfully added to your